Australia TGA reviews processes for minor variations to prescription medicines
This article was originally published in SRA
The Australian Therapeutic Goods Administration is planning to introduce new processes later this year to make it easier for companies to make minor variations to prescription medicines1.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.